LIPOCINE INC (LPCN) Stock Price & Overview
NASDAQ:LPCN • US53630X2036
Current stock price
The current stock price of LPCN is 1.94 USD. Today LPCN is down by -5.37%. In the past month the price decreased by -76.14%. In the past year, price decreased by -36.81%.
LPCN Key Statistics
- Market Cap
- 14.162M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.77
- Dividend Yield
- N/A
LPCN Stock Performance
LPCN Stock Chart
LPCN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LPCN. When comparing the yearly performance of all stocks, LPCN is a bad performer in the overall market: 96.1% of all stocks are doing better.
LPCN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LPCN. LPCN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LPCN Earnings
On March 10, 2026 LPCN reported an EPS of -0.42 and a revenue of 1.15M. The company beat EPS expectations (32.5% surprise) and beat revenue expectations (868.56% surprise).
LPCN Forecast & Estimates
8 analysts have analysed LPCN and the average price target is 13.26 USD. This implies a price increase of 583.51% is expected in the next year compared to the current price of 1.94.
For the next year, analysts expect an EPS growth of -4.31% and a revenue growth -32.9% for LPCN
LPCN Groups
Sector & Classification
LPCN Financial Highlights
Over the last trailing twelve months LPCN reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS decreased by -214.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.61% | ||
| ROE | -66.5% | ||
| Debt/Equity | 0 |
LPCN Ownership
LPCN Latest News, Press Relases and Analysis
LPCN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.52 | 874.551B | ||
| JNJ | JOHNSON & JOHNSON | 20.69 | 580.403B | ||
| MRK | MERCK & CO. INC. | 23.35 | 298.788B | ||
| PFE | PFIZER INC | 9.32 | 158.307B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.37 | 120.824B | ||
| ZTS | ZOETIS INC | 16.71 | 49.921B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.16 | 27.297B | ||
| VTRS | VIATRIS INC | 5.35 | 15.44B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.69 | 11.345B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.682B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.421B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.091B | ||
| CORT | CORCEPT THERAPEUTICS INC | 49.44 | 4.345B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LPCN
Company Profile
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 14 full-time employees. The company went IPO on 2014-03-21. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. The company is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Company Info
IPO: 2014-03-21
LIPOCINE INC
675 S Arapeen Dr Ste 202
Salt Lake City UTAH 84108 US
CEO: Mahesh V. Patel
Employees: 14
Phone: 18019947383
LIPOCINE INC / LPCN FAQ
What does LIPOCINE INC do?
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 14 full-time employees. The company went IPO on 2014-03-21. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. The company is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
What is the current price of LPCN stock?
The current stock price of LPCN is 1.94 USD. The price decreased by -5.37% in the last trading session.
Does LIPOCINE INC pay dividends?
LPCN does not pay a dividend.
What is the ChartMill rating of LIPOCINE INC stock?
LPCN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for LPCN stock?
8 analysts have analysed LPCN and the average price target is 13.26 USD. This implies a price increase of 583.51% is expected in the next year compared to the current price of 1.94.
What is the employee count for LPCN stock?
LIPOCINE INC (LPCN) currently has 14 employees.